Kuki Ichiro, Kawawaki Hisashi, Horino Asako, Inoue Takeshi, Nukui Meguni, Okazaki Shin, Tomiwa Kiyotaka, Amo Kiyoko, Togawa Masao, Shiomi Masashi
No To Hattatsu. 2015 Jan;47(1):32-6.
We performed high-dose erythropoietin therapy (hEPO) for acute encephalopathy or encephalitis (AE), and evaluated its safety and efficacy.
We performed hEPO in AE patients with widespread lesions demonstrated by diffusion-weighted imaging, and prospectively investigated changes in hemoglobin levels, adverse events, changes in images, and developmental quotients.
All four patients showed neither an increase in the hemoglobin level nor adverse event possibly related to hEPO. One patient with acute encephalitis showed resolution of the lesion and normal developmental quotient. Two patients who had acute encephalopathy with febrile convulsive status epilepticus showed mild cerebral atrophy in the recovery phase;one had a normal developmental quotient. The patient with acute necrotizing encephalopathy including a brainstem lesion avoided acute-phase death.
Two patients showed no sequelae despite images indicating widespread abnormality. hEPO could be performed safely in patients with AE, however further trials are necessary concerning its efficacy.
我们对急性脑病或脑炎（AE）患者进行了高剂量促红细胞生成素治疗（hEPO），并评估了其安全性和有效性。
我们对经弥散加权成像显示有广泛病变的AE患者进行了hEPO治疗，并前瞻性地研究了血红蛋白水平的变化、不良事件、图像变化和发育商。
所有4例患者的血红蛋白水平均未升高，也未出现可能与hEPO相关的不良事件。1例急性脑炎患者的病变消失，发育商正常。2例患有急性脑病伴热性惊厥持续状态的患者在恢复期出现轻度脑萎缩；其中1例发育商正常。患有包括脑干病变在内的急性坏死性脑病的患者避免了急性期死亡。
尽管影像学显示有广泛异常，但2例患者未出现后遗症。hEPO可在AE患者中安全进行，然而，关于其疗效还需要进一步试验。
